From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Qbrexza is a prescription medication used to treat excessive underarm sweating, also known as primary axillary hyperhidrosis, and it contains the active ingredient glycopyrronium, which is an anticholinergic compound that works by blocking the chemical signals that activate sweat glands.
Key Points
- Qbrexza comes as a pre-moistened cloth in individually wrapped disposable wipes that are applied once daily to clean, dry underarms 1.
- When using Qbrexza, it's essential to wash hands thoroughly after application to avoid transferring the medication to other areas, particularly the eyes, which could cause pupil dilation and blurred vision 2.
- Common side effects include dry mouth, redness or burning at the application site, headache, and urinary retention 3.
- Qbrexza works by blocking acetylcholine, a neurotransmitter that stimulates sweat gland activity, thereby reducing excessive sweating 4.
- This medication is not intended for heat-induced sweating or generalized sweating conditions and should be used under a doctor's supervision, especially for patients with certain medical conditions like glaucoma or urinary retention issues 5.
Important Considerations
- Qbrexza has been shown to be effective in reducing patient-reported severity of disease and gravimetrically measured sweat production in patients with primary axillary hyperhidrosis 1.
- The medication is generally well tolerated, with most adverse events being mild to moderate in severity 2.
- Qbrexza provides a self-administered, non-invasive alternative to topical antiperspirant therapy and clinic-based treatments in adults with primary axillary hyperhidrosis, and is the only alternative to topical antiperspirants specifically approved in children and adolescents ≥9 years of age 3.